The rise of Sildenafil initially drove a period of growth for pharma, however recent changes present a murky picture for investors. Generic alternatives are eroding profits, and continued litigation add further risk to https://royzyor097177.dailyblogzz.com/41665679/the-blue-pill-and-big-pharma-a-precarious-investment